EnGeneIC Molecular Delivery Pty Ltd
USPTO PatentsView assignee record - 29 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Engeneic ranks #10,607 of 49,997 tracked US assignees by granted-patent volume, with 29 patents across 8 technology areas.
- #10,607
- of 49,997 US assignees by volume
- Top 49%
- by Innovation Score (35.6/100)
- 18.6
- avg claims per patent
- -47%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R10607 · Foreign Corporation #10,607 · 29 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 29 grants
- UPPER-Q #10,607/49,997
- PHOTO-FINISH Eagle Pharmaceuticals
- CPC-NARROW A61K · 8 areas
- INNOV-THIN 35.6/100
- CLAIMS-RICH 18.6 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -47% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Eagle Pharmaceuticals, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Engeneic’s 35.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Engeneic
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Acorn · near
Acorn · near
36 score
- EnGeneIC Molecular… · this assignee
EnGeneIC Molecular… · this assignee
36 score
- Kverneland Group… · near
Kverneland Group… · near
36 score
- Oase · near
Oase · near
36 score
- Tempo Industries · near
Tempo Industries · near
36 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Engeneic's Innovation Score is 35.6/100 (top 49% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Engeneic?
Each dot is one of Engeneic’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Engeneic’s own 18.6 claims/patent is ABOVE the 15.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Engeneic's grants concentrate
EnGeneIC Molecular Delivery Pty Ltd is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2018 (5 grants) versus a trough of 1 in 2016. By volume, Engeneic sits between Etablissement Francais DU Sang (EFS) and FFI Ionix IP, Inc..
Engeneic's three-year grant acceleration
EnGeneIC Molecular Delivery Pty Ltd shows 4 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at EnGeneIC's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Etablissement Fra…
Etablissement Francais DU Sang (EFS)
29 patents
- Eagle Pharmaceuti…
Eagle Pharmaceuticals, Inc.
29 patents
- Controls
Electronic Controls Inc.
29 patents
- Elisa Oyj
Elisa Oyj
29 patents
- Exone
ExOne GmbH
29 patents
- Expensify
Expensify, Inc.
29 patents
- Experian Health
Experian Health, Inc.
29 patents
- FFI Ionix IP
FFI Ionix IP, Inc.
29 patents
- Engeneic Molecula… ◀
EnGeneIC Molecular Delivery Pty Ltd
29 patents
What this shows EnGeneIC holds 29 patents at rank #10,608, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near EnGeneIC
By rank, the assignees closest to #10,608 in granted patent volume.
- Etablissement Francais DU Sang (EFS) #10,604 · 29 patents
- Eagle Pharmaceuticals, Inc. #10,605 · 29 patents
- Electronic Controls Inc. #10,606 · 29 patents
- Elisa Oyj #10,607 · 29 patents
- ExOne GmbH #10,609 · 29 patents
- Expensify, Inc. #10,610 · 29 patents
- Experian Health, Inc. #10,611 · 29 patents
- FFI Ionix IP, Inc. #10,612 · 29 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in EnGeneIC's primary technology class.
- The Regents of the University of California 1,779 in class
- L'Oreal 1,250 in class
- Novartis AG 988 in class
- The Procter & Gamble Company 985 in class
- The Board of Regents of the University of Texas System 950 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 813 in class
- The Trustees of the University of Pennsylvania 768 in class
- Merck Sharp & Dohme LLC 760 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for EnGeneIC, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), EnGeneIC ranks #787 of 7,163 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (36 here).
Engeneic's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
36 Top 49% higher than 51% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 10.3% |
| 2016 | 1 | 3.4% |
| 2017 | 3 | 10.3% |
| 2018 | 5 | 17.2% |
| 2019 | 5 | 17.2% |
| 2020 | 2 | 6.9% |
| 2021 | 3 | 10.3% |
| 2022 | 3 | 10.3% |
| 2024 | 1 | 3.4% |
| 2025partial year | 3 | 10.3% |
Which technologies does EnGeneIC Molecular Delivery Pty Ltd patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
EnGeneIC Molecular Delivery Pty Ltd's patent record in context - here's where to go next.
- EnGeneIC Molecular Delivery Pty Ltd's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
- Ranked #10,607 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare EnGeneIC Molecular Delivery Pty Ltd against Etablissement Francais DU Sang (EFS), an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 35.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.